AstraZeneca expands their first line cancer immunotherapy programme

AstraZeneca has expanded a late-stage trial that assess a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy. The Phase III MYSTIC trial was originally designed to assess the benefit of durvalumab monotherapy and a combination of durvalumab

Continue Reading

Cancer Research UK reports immunotherapy drug that can extend life of cancer patients

A drug that ‘reinvigorates the immune system’ can extend the lives of lung cancer patients with reduced side effects, according to preliminary results from a late stage clinical trial. “This is another great example of how research into the immune system can deliver powerful new treatments” – Professor Peter Johnson, Cancer Research UK. Patients with

Continue Reading